Pernix Therapeutics (Nasdaq: PTX) 17.7% LOWER; updated its full-year 2015 net sales guidance and business outlook. The Company anticipates net sales for the three-months ended March 31, 2015, will be between $32 million and $35 million, compared with $19 million for the same period in 2014. (The Street sees Q1 revenue $49.5 million.)
I am posting this blurb that is one analyst's opinion which is probably causing the decline in the stock price.
Negative on Inuvo, Inc.
10:04 AM ET, 04/16/2015
repeewStreetSehT issued a negative report on Inuvo, Inc..
From the report:
This Arkansas-based internet marketing and technology company battles a history of losses and a debilitating business change spurred by Google. Among the top reasons we expect continuing difficulties and a stock decline:
*The internet company's lifeblood - website traffic - has shown a striking decline for INUV's key properties.
*INUV's price-to-earnings is about three to five times higher than its peers, while its EBITDA is a fraction of the EBITDA of PERI and BCOR.
*Net revenues fell in 2014; and the current share price of ~$3 already exceeds the analyst s price target of $2.
Motley Fool, Seeking Alpha and so forth are Bashers who pay Yahoo to provide negative content. The talking heads and analysts are looking at Yahoo 50/50 that the company is going to be bought out withing a year and after that, this type of baloney will no longer thankfully exist.
3 Biotech Stocks That May Disappear Before 2020
Brian Orelli, Sean Williams, and George Budwell, The Motley Fool - Motley Fool - Wed Apr 15, 7:59AM CDT
Brian Orelli: Like George, I'm going to pick a company that's on a boom-or-bust path to an acquisition or bankruptcy: Exelixis. We'll know this year which trail the biotech is headed down.
This quarter, Exelixis expects results from the Meteor clinical trial testing Cometriq against Novartis' Afinitor in patients with kidney cancer who have failed at least one other treatment. If it's successful, Exelixis should be able to generate decent sales of Cometriq, which is currently approved to treat fairly rare thyroid cancer but is hardly putting a dent in the company's cash burn.
In the latter half of the year -- on or before Aug. 11 -- Exelixis will find out if its second drug, cobimetinib, which is licensed by Roche, will be approved by the Food and Drug Administration. The duo wants to market the drug as a treatment for advanced melanoma patients with tumors that contain a BRAF V600 mutation.
An approval of cobimetinib, which seems likely, would make Exelixis a takeover target for Roche because an acquisition would allow the pharma to avoid sharing profits from cobimetinib with Exelixis. A successful Meteor trial would result in a higher takeover price, but Cometriq would fit into Roche's stable of oncology drugs, so it might even make a takeout more likely.
In the unfortunate situation where the Meteor trial failed and cobimetinib wasn't approved, Exelixis would be left in a precarious situation, where bankruptcy or a fire sale to an opportunistic acquirer would be the most likely outcome.
HC Wainwright upgraded Aeterna Zentaris, Inc. to Buy with price target $1.25. Previously HC Wainwright rated Neutral Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 11/06/2014, when the stock price was $0.68. Since then, Aeterna Zentaris, Inc.'s stock price has lost 13% as of 04/14/2015's recent price of $0.59.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.
while the report shows that retail investors have made a mass exodus.
I believe that there is a delay of a potential surge to possibly $0.80 initially and then with an additional surge to above $1 a share. The stock being a penny stock trading under $1 a share, news of the FDA meeting having just been issued is not on the market radar at this moment.
Mark Zuckerberg and company have filed for a patent suggesting they are interested in creating an ad exchange that would marry advertising data with Facebook’s social graph (i.e. all the data they have collected on their users). Given how much information Facebook has on us that’s an extraordinary advantage for an advertiser to have.
Once those two sets of information are combined the ad could take the form of a video on Facebook or an interactive “app” on another partner site.
While a bit complicated the bottom line is this: Google no longer has the market cornered on your personal information and those valuable online ad dollars may one day flow to Facebook instead.
Facebook’s “social graph is head and shoulders above any type of data that’s out there on the consumer that has ever existed,” says Yahoo Finance’s Phil Pearlman. “It is a huge threat to Google over a longer period of time.”
Pearlman admits Google was the first on the internet advertising scene and they turned it into a “cash cow” for the company. Facebook has since come along to play the role of disrupter while Google instead pumps money into R&D projects like internet balloons (note: Facebook has their own R&D internet drones).
It’s a change Wall Street has noticed too. Facebook’s stock is up 12% in the last six months while Google remains largely unchanged.
“Google has been an incredible cash generating machine,” notes Yahoo Finance’s Aaron Task, “but there are threats and that’s why it’s not just throwing money at the wall and seeing what sticks... they see that the audience is going to mobile, that they’re not as dominant in mobile and that Facebook is an 8,000 pound gorilla in the room.”
(There is more)
A handful of stocks that I bought a block of at $1 that surged to several dollars, had a step sell off one day so I sold to take profits and then they took off and ran into the $30's and $40's. I recovered and found new gems, but I will hold here as I have learned a few painful lessons along the way.
Conway-based tech companies Inuvo and PrivacyStar jointly announced at a Thursday news conference at the Little Rock Regional Chamber of Commerce their plans to relocate to Little Rock’s River Market District.
Digital publishing and advertising technology firm Inuvo signed a five-year lease for office space in the Museum Center building at 500 President Clinton Ave.
The majority of Inuvo’s 53 employees will relocate to the third floor’s 13,000 square-foot offices in early fall, the company said.
Inuvo has undergone significant growth since moving to Arkansas from New York in 2013, Inuvo Chairman and CEO Richard Howe said.
“In Arkansas we have seen an incredible reception to our business,” Howe said, crediting the success to the talent pool in the state. “We had the best year the company has ever had in 2014,” Howe said, adding that the company made revenue of $50 million a year.
Both Inuvo and PrivacyStar are currently housed in the same building at 1111 Main St. in Conway.
PrivacyStar, a smartphone app that blocks unwanted calls and allows users to perform reverse phone lookup searches, will also make the move to the Museum Center, on the second floor.
“We are very much like Inuvo, we need good technology workers,” PrivacyStar Chairman and CEO Charles Morgan said. “We have a lot of programing and tech problems to solve and the kind of people that we’ve been able to find in Arkansas have done a fabulous job.”
Morgan said the company has added 30-40 jobs in the past 12 months, and he expects that kind of growth in the future.
I am noticing on the historical chart that the stock traded at $60 to $30 between 2004 and 2008. What is the circumstance behind that and the current share price?